PharmaCyte Biotech's total assets for Q2 2026 were $55.98M, an increase of 24.09% from the previous quarter. PMCB total liabilities were $19.42M for the fiscal quarter, a 1178.74% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.